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Impact factor for 2012 has just been released. The impact
factor of Clinical Microbiology and Infection increased
slightly this year from 4.540 to 4.578 (Table 1). It is a
marker among others, but it is more pleasant to see it
evolve in a positive rather than a negative way. It is
calculated based on the citations of the year 2012 on
articles 2010 and 2011 divided by the number of articles in
2012. Because of backlog that had been accumulated in the
time of publications, CMI issues were substantial with 421
papers published in 2009, 328 in 2010, 366 in 2011 and 385
in 2012 [1,2].
Interestingly the impact factor has just been the subject of
petition from researchers who refuse to have it used in the
evaluation of their careers [3]. This is interesting but it is
difﬁcult to have a deﬁnite position on this matter. The
impact factor is a witness to the quality of a journal at a
given moment in a given specialty, and also reﬂects the
number of scientists working on this ﬁeld. For example in
infectious diseases, a paper on AIDS has a greater chance to
be a highly cited paper, as more than 7000 articles are
published yearly in this ﬁeld, than one on Tropheryma
whipplei, the agent of Whipple’s disease, with 412 articles
in 20 years! (Table 2) This variation by ﬁeld and domain
should be taken in consideration when evaluating research-
ers’ curriculum vitae (CV). However having referenced
articles in successful journals demonstrates that the articles
have resisted competition whose difﬁculty is directly related
to the impact factor. In fact most authors are now looking to
send their articles to journals with the highest impact factor
possible and thus the competition is becoming more difﬁcult
in high impact factor journals. Thus in Clinical Microbiology
and Infection we now reject 82% of original articles due to
the growth of our impact factor.
Indeed it is undoubtedly a marker of competitiveness. It
is not the only marker for researchers of a certain age, for
whom elements such as the total number of citations, the
H factor, may also play a role in evaluation. In any case,
we cannot underestimate the importance of these objective
markers that prevent, as I often had the opportunity to
observe, pure subjectivity (often disguising friendship,
enmity or intent to avoid competition) in evaluating
researchers.
Finally, the impact factor of journals raises competition
between journals and promotes politics of quality for
editors. Authors have many choices as the number of
journals is increasing. In contrast there is no or little
competition between grants and when searching promotions
where the subjectivity of a single evaluator can destroy a
career, if it is not tempered by the objectivity of the
ranking journals in which the authors have published. Impact
factor will remain a marker more objective than a single
round of peer reviewing used for grants or promotion.
Therefore, the multiple opportunities to be reviewed in a
journal makes the evaluation based on ranking of published
paper far more fair than that based on grant proposals as
recently shown.
TABLE 1. Ranking by impact factor
Journal mainly devoted
to infectious diseases
including practice
Impact factor for 2012
(excluding journals
publishing only reviews)
Lancet Infectious Diseases 19.966
Clinical Infectious Diseases 9.374
AIDS 6.407
Emerging Infectious Diseases 5.993
Journal of Infectious Diseases 5.848
Journal of Antimicrobial Chemotherapy 5.338
JAIDS 4.653
Clinical Microbiology and Infection 4.578
International Journal of Antimicrobial Agents 4.415
Journal of Infection 4.073
TABLE 2. Number of papers published by ﬁeld per year
(source Pub Med)
AIDS 7000
Tuberculosis 6000
Inﬂuenza 5500
Staphylococcus aureus 4000
Malaria 3500
Pseudomonas aeruginosa 2000
Candida albicans 1500
Helicobacter pylori 1500
Streptococcus pneumoniae 1000
Lyme disease 350
Metallo-b-lactamase 200
Coxiella burnetii 150
Tropheryma whipplei 30
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